SHENZHEN, China, July 31 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com announced today that its registration dossier for MEVAC-DTaP (Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, adsorbed) had passed the preliminary consideration of the experts in Thai FDA. The sample analysis is expected to be completed within the next 30 days.
Mr. Terry Yuan CEO of HTDS said (sic) "We welcome the expanded role of the medical team in Serbia. There has been a great synergy between the medical group in Serbia and us here in China, right from day one. I have great admiration for the work they are doing which is simply amazing. It is our goal and target to see the fruits of our labour begin to pay off for us and all of our shareholders.
HTDS was a company acquired by the new management, with the backing of our financiers' under duress, just less than a year ago. Many of HTDS long time shareholders basically witnessed HTDS share values dwindle down to next to nothing. Our goal is to reverse that trend and we believe we are well under way. We have received a number of inquiries about an open Regulation D financing and filing we did. HTDS is a medical company engaged in both RD and vaccine distribution as its core business. Over the next several weeks and months we will be issuing many updates as to what progress the company made. By that we mean, how this financing was used, what equipment was acquired, contracts signed and what assets were acquired, and more importantly the forward strides we made as a company. Our days of being under duress and in peril are well behind us now.
Today, in less than a year we have two very vibrant companies in HTDS. We are focused, determined and the two companies are working hard and there is great synergy and sync between us all. The Mellow Hope division generates revenues and steady cash flows that a business is judged upon, and generally valuated. Slavica Bio Chem on the other hand is a company whose research and development can have astronomical growth impact on our whole organization, and our share price, which by all accounts I can safely say continues to be very undervalued"
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc. 's control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved